Table 2 Baseline characteristics of the breast cancer patient cohort
From: L-arginine dependence of breast cancer – molecular subtypes matter.
Total cohort | Deceased | Survived | p | Recurrence | No recurrence | p | |
|---|---|---|---|---|---|---|---|
Demographics/Anthropometrics | |||||||
N | 243 | 34 (14.0) | 209 (86.0) | ̶ | 47 (19.3) | 196 (80.7) | ̶ |
Age (years) | 60.2 ± 13.2 | 58.7 ± 15.1 | 60.4 ± 12.9 | n.s. | 56.6 ± 15.2 | 61.0 ± 12.6 | 0.040 |
Weight (kg) | 71.8 ± 13.9 | 75.0 ± 18.7 | 71.4 ± 13.0 | n.s. | 70.3 ± 14.1 | 72.2 ± 13.9 | n.s. |
Height (cm) | 165.8 ± 6.9 | 164.6 ± 5.6 | 166.0 ± 7.1 | n.s. | 164.6 ± 5.7 | 166.1 ± 7.2 | n.s. |
BMI | 26.2 ± 5.2 | 27.7 ± 7.2 | 25.4 ± 4.8 | n.s. | 26.0 ± 5.4 | 26.2 ± 5.1 | n.s. |
Family history | 133 | 17 (12.8) | 116 (87.2) | n.s. | 31 (23.3) | 102 (76.7) | n.s. |
History of other malignancies | 45 | 8 (17.8) | 37 (82.2) | n.s. | 14 (31.1) | 31 (68.9) | 0.026 |
Histological Subtype | |||||||
IDC | 181 | 29 (16.0) | 152 (84.0) | n.s. | 36 (19.9) | 145 (90.1) | n.s. |
ILC | 30 | 3 (10.0) | 27 (90.0) | 5 (6.7) | 25 (83.3) | ||
DCIS / LCIS | 21 | 1 (4.8) | 20 (95.2) | 6 (28.6) | 15 (71.4) | ||
Other | 11 | 1 (9.1) | 10 (88.9) | 0 | 11 (100.0) | ||
Tumor staging | |||||||
T1 | 138 | 17 | 121 | n.s. | 23 | 115 | n.s. |
T2 | 66 | 13 | 53 | 15 | 51 | ||
T3 | 9 | 2 | 7 | 2 | 7 | ||
T4+ | 5 | 1 | 4 | 2 | 3 | ||
Tis | 21 | 1 | 18 | 5 | 14 | ||
T not specified | 4 | 0 | 6 | 0 | 4 | ||
N0 | 145 | 18 | 127 | n.s. | 21 | 124 | n.s. |
N1 | 55 | 8 | 47 | 12 | 43 | ||
N2 | 18 | 4 | 14 | 4 | 14 | ||
N not specified | 25 | 4 | 21 | 10 | 15 | ||
M0 | 83 | 16 | 67 | n.s. | 20 | 63 | n.s. |
M1 | 5 | 2 | 3 | 2 | 3 | ||
M not specified | 155 | 16 | 139 | 25 | 130 | ||
Lymphatic invasion | 43 | 9 | 34 | n.s. | 11 | 32 | n.s. |
Vascular invasion | 3 | 1 | 2 | n.s. | 1 | 2 | n.s. |
Breast cancer subtypes and proliferation marker status | |||||||
Luminal A | 111 (45.7) | 14 (12.6) | 97 (87.4) | n.s. | 12 (10.8) | 99 (89.2) | 0.009 |
Luminal B | 67 (27.6) | 9 (13.4) | 58 (86.6) | 19 (28.4) | 48 (71.6) | ||
HER2-positive | 17 (7.0) | 3 (17.6) | 14 (82.4) | 2 (11.8) | 15 (88.8) | ||
Triple-negative | 36 (14.9) | 8 (22.2) | 28 (77.8) | 11 (30.6) | 25 (69.4) | ||
Ki67 ≥ 20% | 103 (42.4) | 18 (17.5) | 85 (82.5) | n.s. | 26 (25.2) | 77 (74.8) | 0.013 |
Oncological treatment in addition to surgery | |||||||
Endocrine therapy | 136 (56.0) | 20 (58.8) | 116 (55.5) | n.s. | 23 (50.0) | 113 (57.7) | n.s. |
Chemotherapy | 96 (39.5) | 17 (50.0) | 79 (37.8) | n.s. | 24 (52.2) | 72 (36.7) | n.s. |
Radiotherapy | 195 (80.2) | 26 (76.5) | 169 (80.9) | n.s. | 33 (70.2) | 162 (82.7) | 0.034 |